These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 1921702)

  • 1. [Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease].
    Bojarska-Szmygin A; Ciechanek R
    Wiad Lek; 2003; 56(7-8):303-7. PubMed ID: 14969154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
    Schott M; Morgenthaler NG; Fritzen R; Feldkamp J; Willenberg HS; Scherbaum WA; Seissler J
    Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients.
    Tamai H; Hayaki I; Kawai K; Komaki G; Matsubayashi S; Kuma K; Kumagai LF; Nagataki S
    J Clin Endocrinol Metab; 1995 May; 80(5):1481-4. PubMed ID: 7744989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antithyrotropin receptor antibodies in a series of Basedow's disease].
    Vidal E; Antoine E; Nadalon S; Cevallos R; Bournaud E; Vandroux JC; Bordessoule D; Loustaud V; Weinbreck P; Liozon F
    Ann Med Interne (Paris); 1988; 139(5):331-5. PubMed ID: 2462393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease.
    Bojarska-Szmygin A; Janicki K; Pietura R; Janicka L
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):248-53. PubMed ID: 15314994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [TSH receptor antibodies in the recurrent goiter after surgical treatment of Graves-Basedow disease].
    Janowska J; Widala E; Zych F
    Pol Merkur Lekarski; 1998 May; 4(23):257-8. PubMed ID: 9825656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
    Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
    Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
    Rink T; Holle LH; Schroth HJ; Garth H
    Nuklearmedizin; 1998 May; 37(3):90-4. PubMed ID: 9604228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of thyroxine upon prevention of recurrence of Graves' disease treated with antithyroid drugs].
    Wu G; Jie Y; Situ Y
    Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):274-5. PubMed ID: 11798886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of cells expressing the human thyrotropin (TSH) receptor for the measurement of thyroid stimulating and TSH-blocking antibodies.
    Vitti P; Chiovato L; Fiore E; Mammoli C; Rocchi R; Pinchera A
    Acta Med Austriaca; 1996; 23(1-2):52-6. PubMed ID: 8767515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
    Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G
    Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro suppression of anti-TSH receptor antibody by autologous anti-idiotypic antibody in patients with Graves' disease.
    Balázs C; Molnár I
    Acta Microbiol Immunol Hung; 1995; 42(2):163-9. PubMed ID: 7551709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prospective study on the relationship between treatment duration of antithyroid drug and remission rate of Graves' disease].
    Liu C; Duan Y; Wu X
    Zhonghua Yi Xue Za Zhi; 2000 Nov; 80(11):835-7. PubMed ID: 11218878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The prognostic value of thyroid stimulating antibodies after antithyroid drug treatment of Graves' disease].
    Li J; Gao H; Xu L
    Zhonghua Yi Xue Za Zhi; 1994 Apr; 74(4):218-20, 254-5. PubMed ID: 7922762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TSH-receptor autoantibodies - differentiation of hyperthyroidism between Graves' disease and toxic multinodular goitre.
    Wallaschofski H; Kuwert T; Lohmann T
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):171-4. PubMed ID: 15127319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [TSH receptor antibodies as a recurrence index of Graves disease treated with antithyroid drugs].
    Arqueros MC; el Tamer E; el Tamer S; Houssay AB
    Medicina (B Aires); 1991; 51(1):9-13. PubMed ID: 1921702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graves' disease: evolution and prognosis after eight months of treatment with methimazole.
    Gauna AT; Guillén CE; Sartorio GC; Soto RJ
    Medicina (B Aires); 1992; 52(3):207-12. PubMed ID: 1364158
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.